接受CT或MRI筛查的高危患者中LI-RADS v2018不同类别的患病率
本回顾性研究纳入2018年8月至2020年4月因肝细胞癌筛查行CT或MRI检查的329例患者,从报告中提取肝脏病灶观察数及LI-RADS v2018类别。结果显示60%患者无报告病灶,6%患者有可能或明确恶性病灶。
要点
- 329例筛查患者中60%(199/329)无报告肝脏观察灶。
- 130例患者共报告166个观察灶,其中LR-1占68.7%(114/166)。
- 6%(20/329)患者有可能或明确恶性观察灶(LR-4、LR-5、LR-M或LR-TIV)。
核心结论
- 在因肝细胞癌筛查行增强CT/MRI的高危患者队列中,60%无肝脏观察灶,6%有可能或明确恶性观察灶。
研究设计与样本
- 回顾性研究,纳入2018年8月至2020年4月因肝细胞癌筛查行CT或MRI检查的全部报告,共329例患者(170例[52%]男性,平均年龄59岁[SD 12])。
关键影像表现/征象
- 177例(54%)行钆塞酸增强MRI,72例(22%)行细胞外对比剂MRI,7例(2%)行对比剂未注明MRI,73例(22%)行CT。
- 130例患者共报告166个观察灶:LR-1 114个(68.7%)、LR-2 8个(4.8%)、LR-3 21个(12.6%)、LR-4 6个(3.6%)、LR-5 13个(7.8%)、LR-M 3个(1.8%)、LR-TIV 1个(0.6%)。
- 114个LR-1观察灶中,囊肿78个(68%)、血管瘤17个(15%)、血管分流12个(11%)、局灶性结节性增生3个(3%)、含铁结节2个(2%)、脂肪瘤1个(1%)、胆管错构瘤1个(1%)。
诊断标准与关键数值
- LI-RADS v2018类别分布:LR-1 68.7%(114/166)、LR-2 4.8%(8/166)、LR-3 12.6%(21/166)、LR-4 3.6%(6/166)、LR-5 7.8%(13/166)、LR-M 1.8%(3/166)、LR-TIV 0.6%(1/166)。
- 可能或明确恶性类别(LR-4、LR-5、LR-M或LR-TIV)共23个观察灶,见于20/329例(6%)患者。
临床应用与阅片要点
- CT或MRI用于肝细胞癌筛查时LI-RADS v2018各类别的患病率数据,可帮助制定筛查标准并评估CT和MRI监测策略的成本效益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To estimate the prevalence of Liver Imaging Reporting and Data System (LI-RADS, LR) v2018 categories reported on CT or MRI performed for hepatocellular carcinoma (HCC) screening.
MATERIALS AND METHODS: This retrospective study included all reports for CT and MRI exams performed for HCC screening patients between 8/2018 and 4/2020. Patients with ultrasound, CT, or MRI of the abdomen within two years of the index exam were excluded. From each radiology report, we extracted number of reported liver observations, and LI-RADS v2018 category for each observation.
RESULTS: There were 329 patients (170 [52%] male, mean age 59 years [SD 12]), of whom 177 (54%) had MRI with gadoxetate, 72 (22%) had MRI with extracellular contrast, 7 (2%) had MRI with unspecified contrast, and 73 (22%) had CT. Of 329 patients, 199 (60%) had no reported observations; 130 patients had 166 reported observations: 114 (68.7%) LR-1, 8 (4.8%) LR-2, 21 (12.6%) LR-3, 6 (3.6%) LR-4, 13 (7.8%) LR-5, 3 (1.8%) LR-M, and 1 (0.6%) LR-TIV. Of 114 LR-1 observations, 78 (68%) were cysts, 17 (15%) were hemangiomas, 12 (11%) were vascular shunts, 3 (3%) were focal nodular hyperplasia, 2 (2%) were siderotic nodules, 1 (1%) was a lipoma, and 1 (1%) was biliary hamartoma. There were 23 observations with probably or definitely malignant categories (LR-4, LR-5, LR-M or LR- TIV), reported in 20/329 (6%) of patients.
CONCLUSION: In a cohort of at-risk patients undergoing contrast-enhanced CT/MRI for HCC screening, 60% of had no liver observations, and 6 % had probably or definitely malignant observations.
IMPLICATIONS FOR PATIENT CARE: The prevalence of LI-RADS v2018 categories on CT or MR exams used for HCC screening can help develop screening criteria and assess cost-effectiveness of surveillance strategies with CT and MRI.
引用
- Shahbazian H, Birnbaum J, Burns PJ, et al. Prevalence of different LI-RADS v2018 categories in high-risk patients undergoing CT- or MRI-based screening for hepatocellular carcinoma. Abdom Radiol (NY). 2023. PMID: 37725110. doi:10.1007/s00261-023-04040-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。